CY1125297T1 - Αναστολεις της il-8 για χρηση στην αγωγη της περιφερικης νευροπαθειας που επαγεται απο χημειοθεραπεια - Google Patents

Αναστολεις της il-8 για χρηση στην αγωγη της περιφερικης νευροπαθειας που επαγεται απο χημειοθεραπεια

Info

Publication number
CY1125297T1
CY1125297T1 CY20211100886T CY211100886T CY1125297T1 CY 1125297 T1 CY1125297 T1 CY 1125297T1 CY 20211100886 T CY20211100886 T CY 20211100886T CY 211100886 T CY211100886 T CY 211100886T CY 1125297 T1 CY1125297 T1 CY 1125297T1
Authority
CY
Cyprus
Prior art keywords
chemotherapy
treatment
inhibitors
peripheral neuropathy
induced peripheral
Prior art date
Application number
CY20211100886T
Other languages
Greek (el)
English (en)
Inventor
Laura Brandolini
Pier Adelchi Ruffini
Marcello Allegretti
Original Assignee
Dompé Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16151618.2A external-priority patent/EP3192504A1/en
Application filed by Dompé Farmaceutici S.P.A. filed Critical Dompé Farmaceutici S.P.A.
Publication of CY1125297T1 publication Critical patent/CY1125297T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CY20211100886T 2016-01-15 2021-10-14 Αναστολεις της il-8 για χρηση στην αγωγη της περιφερικης νευροπαθειας που επαγεται απο χημειοθεραπεια CY1125297T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16151618.2A EP3192504A1 (en) 2016-01-15 2016-01-15 Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
EP16190871 2016-09-27
PCT/EP2017/050637 WO2017121838A1 (en) 2016-01-15 2017-01-13 Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy

Publications (1)

Publication Number Publication Date
CY1125297T1 true CY1125297T1 (el) 2023-03-24

Family

ID=57906595

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100886T CY1125297T1 (el) 2016-01-15 2021-10-14 Αναστολεις της il-8 για χρηση στην αγωγη της περιφερικης νευροπαθειας που επαγεται απο χημειοθεραπεια

Country Status (23)

Country Link
US (2) US12268671B2 (cg-RX-API-DMAC10.html)
EP (1) EP3402474B1 (cg-RX-API-DMAC10.html)
JP (1) JP7049254B2 (cg-RX-API-DMAC10.html)
KR (1) KR102737378B1 (cg-RX-API-DMAC10.html)
CN (1) CN108463219B (cg-RX-API-DMAC10.html)
AU (1) AU2017207850B2 (cg-RX-API-DMAC10.html)
CA (1) CA3009438A1 (cg-RX-API-DMAC10.html)
CY (1) CY1125297T1 (cg-RX-API-DMAC10.html)
DK (1) DK3402474T3 (cg-RX-API-DMAC10.html)
ES (1) ES2893701T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20211527T1 (cg-RX-API-DMAC10.html)
HU (1) HUE056606T2 (cg-RX-API-DMAC10.html)
IL (1) IL260373B (cg-RX-API-DMAC10.html)
LT (1) LT3402474T (cg-RX-API-DMAC10.html)
MA (1) MA43861A (cg-RX-API-DMAC10.html)
MX (1) MX388815B (cg-RX-API-DMAC10.html)
PL (1) PL3402474T3 (cg-RX-API-DMAC10.html)
RS (1) RS62427B1 (cg-RX-API-DMAC10.html)
SG (1) SG11201804484YA (cg-RX-API-DMAC10.html)
SI (1) SI3402474T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202100571T1 (cg-RX-API-DMAC10.html)
WO (1) WO2017121838A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201803486B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101914358B1 (ko) * 2017-01-18 2018-11-02 현대로템 주식회사 실내등 제어회로 및 이를 포함하는 철도차량
CN111343973A (zh) * 2017-10-24 2020-06-26 多姆皮制药公司 用于治疗一些肉瘤的il-8抑制剂
EP3476390A1 (en) 2017-10-24 2019-05-01 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of sarcomas
EP3498269A1 (en) * 2017-12-12 2019-06-19 Dompé farmaceutici S.p.A. C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
CA3196979A1 (en) * 2020-11-05 2022-05-12 Icahn School Of Medicine At Mount Sinai Cxcr1/cxcr2 inhibitors for use in treating myelofibrosis
EP4052702A1 (en) * 2021-03-04 2022-09-07 Dompé farmaceutici S.p.a. Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of seizures
EP4397305A1 (en) * 2023-01-05 2024-07-10 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
HRP20090681T1 (hr) 2004-03-23 2010-02-28 Dompe' S.P.A. Derivati 2-fenilpropionske kiseline i farmaceutski pripravci koji ih sadrže
EP2066335A4 (en) * 2006-09-26 2010-01-20 Univ Case Western Reserve ZYTOKINSIGNALISIERUNG
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
CR20160557A (es) 2014-05-29 2017-01-20 Glaxosmithkline Ip Dev Ltd Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2
KR20170036753A (ko) * 2014-07-31 2017-04-03 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화학요법 유도된 말초 신경병증 (cipn)의 예방 및/또는 치료를 위한 cxcr2 길항제의 용도

Also Published As

Publication number Publication date
US12268671B2 (en) 2025-04-08
MX2018008614A (es) 2018-11-19
CN108463219A (zh) 2018-08-28
CA3009438A1 (en) 2017-07-20
US20250195479A1 (en) 2025-06-19
EP3402474A1 (en) 2018-11-21
SI3402474T1 (sl) 2021-12-31
AU2017207850A1 (en) 2018-06-21
SMT202100571T1 (it) 2021-11-12
BR112018013570A2 (pt) 2018-12-11
ES2893701T3 (es) 2022-02-09
DK3402474T3 (da) 2021-10-11
LT3402474T (lt) 2021-11-25
MA43861A (fr) 2021-05-05
MX388815B (es) 2025-03-20
PL3402474T3 (pl) 2021-12-27
KR20180101390A (ko) 2018-09-12
HRP20211527T1 (hr) 2021-12-24
RS62427B1 (sr) 2021-11-30
SG11201804484YA (en) 2018-07-30
AU2017207850B2 (en) 2022-06-30
ZA201803486B (en) 2019-09-25
NZ743344A (en) 2024-05-31
WO2017121838A1 (en) 2017-07-20
US20190015391A1 (en) 2019-01-17
JP2019501948A (ja) 2019-01-24
CN108463219B (zh) 2021-09-17
EP3402474B1 (en) 2021-07-21
JP7049254B2 (ja) 2022-04-06
HUE056606T2 (hu) 2022-02-28
IL260373B (en) 2021-03-25
KR102737378B1 (ko) 2024-12-04

Similar Documents

Publication Publication Date Title
CY1126132T1 (el) Πυριδαζινονες ως αναστολεις parp7
CY1125245T1 (el) Ετεροκυκλικες ενωσεις ως αναστολεις ρι3κ-γαμμα
CY1122314T1 (el) Κυκλοπροπυλαμινες ως αναστολεις lsd1
CY1125327T1 (el) Anti-pd-1 αντισωματα και συνθεσεις
CO2021001893A2 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
CY1123561T1 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
LT3986897T (lt) Egfr inhibitorius, skirtas vėžiui gydyti
CY1123833T1 (el) Μεθοδοι προληψης καρδιαγγειακων συμβαντων σε δυσλιπιδαιμικους πληθυσμους υπολειπομενου κινδυνου
EA202091540A1 (ru) Антитела к lilrb2
CY1126020T1 (el) Κ1ναζολινονες ως αναστολεις parp14
CY1121360T1 (el) Αναστολεις dna-pk
EA202092435A3 (ru) Моноклональные антитела против bcma
CY1120556T1 (el) Δικυκλικα ετεροκυκλα ως αναστολεις fgfr
CL2017003261A1 (es) Factor xi anticuerpos y métodos de uso
PE20171556A1 (es) Agentes de union a cd123 y usos de estos
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
PE20170256A1 (es) Proteinas de union y sus metodos de uso
EA201691541A1 (ru) Новые анти-baff антитела
MX388815B (es) Inhibidores de il-8 para usarse en el tratamiento de neuropatia periferica inducida por quimioterapia.
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
CY1120459T1 (el) Αντισωματα των χημειοκινων παν-elr+ cxc
CY1123231T1 (el) Ενωσεις τετραϋδροπυριμιδοδιαζεπινης και τετραϋδροπυριδοδιαζεπινης για θεραπεια πονου και καταστασεων σχετικων με τον πονο
BR112017002060A2 (pt) novo uso
CY1122445T1 (el) Ανταγωνιστες διαυλου καλιου kv1.3